KEY FINDINGS
The global infertility testing & treatment market is projected to register a CAGR of 10.63% over the forecasting period of 2021 to 2028. The market growth is facilitated by key factors such as, rising stress and lifestyle disorders, increased age of conception, the surging government support, and elevating effectiveness of treatment.
MARKET INSIGHTS
Infertility is characterized as the inability to get pregnant, despite engaging in carefully timed and unprotected intercourse for 12 months. Although the cause of infertility is often difficult to determine, it may include insufficient levels of specific hormones in both women and men, in addition to problems with ovulation in women. Infertility tests typically include several special procedures, semen analysis, physical exams, and blood tests.
Aging significantly affects fertility. A woman’s ability to conceive begins to reduce after the age of 35. Furthermore, male fertility begins to decrease around the age of 40 to 45, with the reduction of sperm quality. Hence the demand for infertility testing and treatment solutions is continually rising. Age-related infertility is often perceived as an issue that can be easily resolved by assisted conception. As a result, the demand for infertility drugs rises as the rates of late pregnancies surge.
REGIONAL INSIGHTS
The global infertility testing & treatment market growth assessment includes an in-depth analysis of the Asia-Pacific, Europe, North America, and the Rest of World. The Asia-Pacific is set to grow with the highest CAGR over the forecast period, primarily owing to the rise in fertility tourism and the surging adoption of fertility procedures. Besides, relatively cheaper treatments in countries such as Singapore, Malaysia, Thailand, South Korea, and India further augment the regional market’s growth.
COMPETITIVE INSIGHTS
The industry rivalry is expected to be high in the market on account of the availability of multiple infertility testing & treatment market players. Moreover, the increasing rate of infertility rate as well as healthcare expenditures attracts potential investors to invest in the global market, thereby reinforcing the competition. Some of the key companies operating in the market are CooperSurgical, EMD Group (Merck KGaA), Fujifilm Irvine Scientific, Cook Medical Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING STRESS AND LIFESTYLE DISORDERS
3.1.2. INCREASED AGE OF CONCEPTION
3.1.3. INCREASING EFFECTIVENESS OF TREATMENTS
3.1.4. RISING GOVERNMENT SUPPORT
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF TESTING AND TREATMENT
3.2.2. INFERTILITY CONSIDERED A SOCIAL TABOO
3.2.3. POSSIBLE RISKS ASSOCIATED WITH INFERTILITY TREATMENTS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON INFERTILITY TESTING & TREATMENT MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
4.6.1. TREATMENT OPTIONS
4.6.2. QUALITY OF MEDICAL PROCEDURES
4.6.3. PRICE OF TREATMENTS
4.6.4. SHIFT TOWARDS MEDICAL TOURISM
4.6.5. REIMBURSEMENT
4.7. REGULATORY FRAMEWORK
4.8. VALUE CHAIN ANALYSIS
4.8.1. RAW MATERIAL PROCUREMENT
4.8.2. MANUFACTURING
4.8.3. SUPPLY LOGISTICS
4.8.4. DISTRIBUTION CHANNELS
4.8.5. END-USERS
5. MARKET BY GENDER
5.1. MALE
5.1.1. MALE INFERTILITY TESTING
5.1.1.1. DNA FRAGMENTATION
5.1.1.2. OXIDATIVE STRESS ANALYSIS
5.1.1.3. SPERM PENETRATION ASSAY
5.1.1.4. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
5.1.1.5. SPERM AGGLUTINATION
5.1.1.6. MICROSCOPIC EXAMINATION
5.1.1.7. OTHERS
5.1.2. MALE INFERTILITY TREATMENT
5.1.2.1. MEDICATION
5.1.2.2. ASSISTED REPRODUCTIVE TECHNOLOGY & VARICOCELE SURGERY
5.2. FEMALE
5.2.1. FEMALE INFERTILITY TESTING
5.2.1.1. OVULATION TESTING
5.2.1.2. HYSTEROSALPINGOGRAPHY
5.2.1.3. LAPAROSCOPY
5.2.1.4. TRANSVAGINAL ULTRASOUND
5.2.1.5. OVARIAN RESERVE TESTING
5.2.1.6. HORMONAL LEVEL TESTING
5.2.1.7. OTHERS
5.2.2. FEMALE INFERTILITY TREATMENT
5.2.2.1. IVF WITH ICSI
5.2.2.2. IUI
5.2.2.3. IVF WITHOUT ICSI
5.2.2.4. SURROGACY
5.2.2.5. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. KEY GROWTH ENABLERS
7.1.2. KEY CHALLENGES
7.1.3. KEY PLAYERS
7.1.4. COUNTRY ANALYSIS
7.1.4.1. UNITED STATES
7.1.4.2. CANADA
7.2. EUROPE
7.2.1. KEY GROWTH ENABLERS
7.2.2. KEY CHALLENGES
7.2.3. KEY PLAYERS
7.2.4. COUNTRY ANALYSIS
7.2.4.1. UNITED KINGDOM
7.2.4.2. GERMANY
7.2.4.3. FRANCE
7.2.4.4. ITALY
7.2.4.5. RUSSIA
7.2.4.6. BELGIUM
7.2.4.7. POLAND
7.2.4.8. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. KEY GROWTH ENABLERS
7.3.2. KEY CHALLENGES
7.3.3. KEY PLAYERS
7.3.4. COUNTRY ANALYSIS
7.3.4.1. CHINA
7.3.4.2. JAPAN
7.3.4.3. INDIA
7.3.4.4. SOUTH KOREA
7.3.4.5. INDONESIA
7.3.4.6. THAILAND
7.3.4.7. VIETNAM
7.3.4.8. AUSTRALIA & NEW ZEALAND
7.3.4.9. REST OF ASIA-PACIFIC
7.4. REST OF WORLD
7.4.1. KEY GROWTH ENABLERS
7.4.2. KEY CHALLENGES
7.4.3. KEY PLAYERS
7.4.4. REGIONAL ANALYSIS
7.4.4.1. LATIN AMERICA
7.4.4.2. MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.2. COMPANY PROFILES
8.2.1. ADORFEM
8.2.2. BANGKOK IVF CENTER
8.2.3. COOK MEDICAL INC
8.2.4. COOPER SURGICAL
8.2.5. CREATE FERTILITY CENTRE
8.2.6. EMD GROUP (MERCK KGAA)
8.2.7. ENDO INTERNATIONAL PLC
8.2.8. ESCO MEDICAL
8.2.9. FERRING PHARMACEUTICALS
8.2.10. FERTILITY FIRST
8.2.11. FUJIFILM IRVINE SCIENTIFIC
8.2.12. GENEA LTD
8.2.13. HALOTECH DNA
8.2.14. HAMILTON THRONE LTD
8.2.15. IVFTECH
8.2.16. LABOTECT GMBH
8.2.17. OLYMPUS CORPORATION
8.2.18. PROGYNY
8.2.19. THERMO FISHER SCIENTIFIC INC
8.2.20. VITROLIFE AB
1. ADORFEM
2. BANGKOK IVF CENTER
3. COOK MEDICAL INC
4. COOPER SURGICAL
5. CREATE FERTILITY CENTRE
6. EMD GROUP (MERCK KGAA)
7. ENDO INTERNATIONAL PLC
8. ESCO MEDICAL
9. FERRING PHARMACEUTICALS
10. FERTILITY FIRST
11. FUJIFILM IRVINE SCIENTIFIC
12. GENEA LTD
13. HALOTECH DNA
14. HAMILTON THRONE LTD
15. IVFTECH
16. LABOTECT GMBH
17. OLYMPUS CORPORATION
18. PROGYNY
19. THERMO FISHER SCIENTIFIC INC
20. VITROLIFE AB
